MRKR Marker Therapeutics Inc.

2.27
-0.2  -8%
Previous Close 2.47
Open 2.5
Price To Book 2.67
Market Cap 105,628,825
Shares 46,532,522
Volume 849,467
Short Ratio
Av. Daily Volume 555,687
Stock charts supplied by TradingView

NewsSee all news

  1. Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

    HOUSTON, May 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  2. ­­­­­­­­­Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

    HOUSTON, May 13, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of

  3. Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

    HOUSTON, May 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  4. Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

    HOUSTON, May 4, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of

  5. Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

    HOUSTON, April 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 program to be discontinued due to lack of efficacy.
TPIV200
Platinum-sensitive ovarian cancer
Phase 2 trial ongoing.
TPIV200
Triple-negative breast cancer (TNBC)
Phase 1/2 trial ongoing.
MultiTAA-Specific T Cells
Lymphoma
Phase 2 clinical hold lifted - February 11, 2020. Replaced with partial hold.
MultiTAA-Specific T Cells
Acute Myeloid Leukemia
Phase 1/2 data update at ASCO May 29, 2020. 4/13 overall responses.
MultiTAA-Specific T Cells
Pancreatic cancer

Latest News

  1. Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

    HOUSTON, May 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  2. ­­­­­­­­­Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

    HOUSTON, May 13, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of

  3. Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

    HOUSTON, May 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  4. Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

    HOUSTON, May 4, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of

  5. Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

    HOUSTON, April 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

  6. Marker Therapeutics Reports Full Year 2019 Operating and Financial Results

    HOUSTON, March 12, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

  7. Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million

    HOUSTON, March 2, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

  8. Marker Therapeutics to Present at Two Upcoming Investor Conferences

    HOUSTON, Feb. 18, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

  9. Marker Therapeutics Announces Update to its Clinical Program in AML

    HOUSTON, Feb. 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  10. Marker Therapeutics to Present at Two Upcoming Investor Conferences

    HOUSTON, Nov. 25, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

  11. Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

    HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment

  12. Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

    HOUSTON, Nov. 11, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment